At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 43 enrolled
Drug / intervention
Selexipagdrug
Likely dose
Selexipag 1600 microgramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Single-arm, Open-label, Long-term Follow-up Safety Study of Selexipag in Participants Who Participated in a Previous Selexipag Study
In Brief
A Phase 3 clinical trial evaluating Selexipag for Hypertension, Pulmonary. Completed, enrolled 43 participants across 13 sites in 6 countries.
Detailed Summary
The purpose of this study is to assess the long-term safety of selexipag while providing continued selexipag treatment for participants who were previously enrolled in an Actelion-sponsored study with selexipag and who derived benefit from selexipag in indications for which a positive benefit-risk has been established.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension, Pulmonary
CountriesBelarus, India, Romania, South Korea, Taiwan, Ukraine
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedSep 2020
Enrollment StartMay 2021
Primary CompletionNov 2023
TodayJul 2026
First PostedSep 28, 2020
Enrollment StartMay 3, 2021
Primary CompletionNov 10, 2023
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 5.8 years ago
Interventions
Selexipagdrug
Selexipag tablets will be administered orally at all dose strengths (200, 400, 600, 800, 1000, 1200, 1400 and 1600 microgram) twice daily.